A Superior Genetic Engineering Platform

Next-Gen Vaccine Vector Technology

Welcome To Greffex

Greffex is a genetic engineering company that has developed next generation Ad vector technology and a superior vaccine platform.  In addition to groundbreaking gene therapy applications, Greffex can become the global vaccine platform standard to fend off future pandemics.

Greffex’s novel vector approach integrates different strategies to overcome the limitations of other vaccine systems.   Greffex vaccines are fully deleted of all endogenous viral genes without the use of helper viruses (we have patented this technology).  

Fully deleted vectors better focus the immune system to a vaccine antigen, minimize interference by anti-adenoviral responses, and enable repeat uses of the same construct.



  • Greffex began as a genetic engineering company working on gene therapy (Hepatitis A, Cystic Fibrosis) and Transplantation  therapies, before pivoting to vaccine development.
  • More recently, Greffex is primarily focused on vaccine development 
  • In 2024 Greffex will have its Avian Flu (H5N1) candidate in Phase 1/2a clinical trials 
    • H5N1 vaccine (NIH)                  Phase 1/2a
    • Universal Flu vaccine (NIH)    Pre-Clinical


  • Greffex’s vaccines have been designed to outperform mRNA and other types of vaccines: 
    • Highly Effective
    • Longer Protection (Greffex can last months longer than mRNA) means fewer shots required
    • Cheaper (mRNA can cost 5x more than Greffex)
    • Easier (and cheaper) to Distribute: No Freezer
    • Reduced interference and increased effectiveness compared to other platforms
  • Greffex holds patents for the creation of a fully-deleted, helper-independent vector platform
  • Using the target disease’s genetic sequence, Greffex can create any vaccine in 3-4 weeks and produce millions of doses at a fraction of the cost of traditional vaccine production
  • NIH-sponsored animal trials demonstrated an impressive 100% survival against H5N1 (versus FDA standard of 70% in animals)

Greffex presently holds 4 patents with over 6 additional filings

Vaccine Candidates in Pipeline

Three vaccine candidates should be entering clinical trials over the next three years, including a Universal Flu vaccine, the H5N1 avian flu vaccine, and a Lyme’s vaccine candidate.

The Greffex Platform


Greffex patented the process to fully delete all endogenous vector genes


Greffex vectors are devoid of contaminating helper or recombinant
replicating viruses

No Freezers

Greffex vectors are genetically stable and can be stored at room


Greffex vectors can outlast mRNA by months reducing the number of shots needed


A fraction of the cost of mRNA


Greffex vectors are manufactured by a standardized highly efficient

Our Team

President and Chief Executive Officer

John R. Price

President and Chief Executive Officer
Chief Scientific Officer

Uwe D. Staerz

Chief Scientific Officer
Executive Vice President

William S. Connolly

Executive Vice President